PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022
April 27, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine
April 25, 2022 07:30 ET
|
PolyPid Ltd.
Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) --...
PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting
April 12, 2022 08:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today...
PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility
April 06, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today...
PolyPid to Deliver Poster Presentation at SAGES 2022
March 08, 2022 07:00 ET
|
PolyPid Ltd.
Presentation Evaluates Efficacy of D-PLEX100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd....
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
March 02, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally...
PolyPid to Present at the Barclays Global Healthcare Conference
March 01, 2022 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
February 09, 2022 07:00 ET
|
PolyPid Ltd.
• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up• Recruitment Progressing as Planned with Approximately...
PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022
January 26, 2022 07:30 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally...
PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board
January 04, 2022 07:30 ET
|
PolyPid Ltd.
Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel,...